Reference Cases
A few of our success stories
Being able to predict which cancer patient is likely to respond to chemotherapy with cisplatin has not yet been possible. However, a unique research project between NRG|PALLAS, the Netherlands Cancer Institute (NKI) and Amsterdam UMC may bring about some change.
Producing medical isotopes using only low enriched uranium? After a challenging design process, Curium and NRG are the first in Europe to produce molybdenum-99 with low enriched uranium. Recognizing the commitments made during the Nuclear Summit 2014, to phase out high enriched uranium (HEU) based medical isotopes.
Recently, we have developed the world’s first fully automated synthesis module, for the synthesis of Pt-195m cisplatin and other platinum compounds
A complex project has been brought to a successful conclusion: the development and installation of a production process for xenon-133 gas.